Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isolagen has reached an agreement with the FDA on the design of its phase III study protocol for the use of Isolagen Therapy in the treatment of wrinkles.
Subscribe to our email newsletter
The protocol was submitted to the FDA under the agency’s special protocol assessment (SPA) regulations. The SPA process allows for FDA evaluation of trial protocol that will form the basis of an efficacy claim for a marketing application, and provides an agreement that the study design is acceptable to the FDA.
“We are eager to begin the Isolagen Therapy registration trials for the treatment of wrinkles and plan to begin enrolling patients as soon as possible,” said Nicholas Teti, Isolagen chairman and CEO.
The phase III trials will evaluate the efficacy and safety of Isolagen Therapy against placebo for the treatment of nasolabial skin fold wrinkles. Each trial will include 200 patients.